GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Float Percentage Of Total Shares Outstanding

Resverlogix (TSX:RVX) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 12, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Resverlogix's float shares is 0.00 Mil. Resverlogix's total shares outstanding is 274.82 Mil. Resverlogix's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Resverlogix's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Resverlogix's Institutional Ownership is 0.01%.

Resverlogix Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Resverlogix's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/274.82
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resverlogix (TSX:RVX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
TSXV:SBM XCNQ:BETR TSX:ATE TSX:AEZS XCNQ:ASEP XCNQ:PREV TSXV:KNE XCNQ:MDMA XCNQ:PHRM XCNQ:BIOV OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
RVXCF:USA RFS:Germany
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Website
https://www.resverlogix.com
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Executives
Aaron Bradley Cann Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines